Search results
Showing 61 to 75 of 187 results for advanced breast cancer
Endoscopic mastectomy and endoscopic wide local excision for breast cancer (IPG296)
Evidence-based recommendations on endoscopic mastectomy and endoscopic wide local excision for breast cancer. This involves removing part or all of the breast using special instruments inserted through small cuts in the skin (keyhole surgery).
View recommendations for IPG296Show all sections
Sections for IPG296
Evidence-based recommendations on olaparib (Lynparza) for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy in adults.
Axxent electronic brachytherapy system for early stage breast cancer (MIB76)
NICE has developed a medtech innovation briefing (MIB) on Axxent electronic brachytherapy system for early stage breast cancer
Everolimus for advanced renal cell carcinoma after previous treatment (TA432)
Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment.
Image-guided radiofrequency excision biopsy of breast lesions (IPG308)
Evidence-based recommendations on image-guided radiofrequency excision biopsy of breast lesions. This involves inserting a probe that uses radiofrequency energy to cut through the breast internally, and removing the lump with a small area of surrounding tissue to test for cancer.
View recommendations for IPG308Show all sections
Sections for IPG308
Evidence-based recommendations on interstitial laser therapy for breast cancer. This involves using laser energy to destroying the cancer cells.
View recommendations for IPG89Show all sections
Evidence-based recommendations on brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision. This involves inserting radioactive sources into the space in the breast where tissue has been removed to minimise the chances of the cancer coming back.
View recommendations for IPG268Show all sections
Sections for IPG268
Find out about the progress made by the health and care system in implementing NICE guidance on prostate cancer
Awaiting development [GID-TA11487] Expected publication date: TBC
Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults.
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.
Effectivness of 26 Gy in 5 fractions over 1 week regimen in people receiving breast construction- What is the effectiveness of...
Endoscopic axillary lymph node retrieval for breast cancer (IPG147)
Evidence-based recommendations on endoscopic axillary lymph node retrieval for breast cancer. This involves using narrow instruments to remove the lymph nodes through small, rather than large, openings to reduce the risk of infection and other problems.
View recommendations for IPG147Show all sections
Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)
NICE has developed a medtech innovation briefing (MIB) on Signatera for detecting molecular residual disease from solid tumour cancers .
in 15 fractions over 3 weeks in people with early or locally advanced invasive breast cancer who are also...